Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.08.2010 | Epidemiology

Socioeconomic disparities in the decline in invasive breast cancer incidence

verfasst von: Brian L. Sprague, Amy Trentham-Dietz, Elizabeth S. Burnside

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer incidence in the United States has declined dramatically since the year 2002. To improve our understanding of the underlying factors driving breast cancer trends, we explored potential socioeconomic disparities in the recent decline in incidence. We examined the decline in breast cancer incidence according to county-level socioeconomic indicators using data from the Surveillance, Epidemiology and End Results (SEER) program. Since socioeconomic status is associated with mammography screening, we also examined the relation between incidence of ductal carcinoma in situ (DCIS; a strong marker of mammography utilization) and the decline in invasive breast cancer. The reduction in invasive breast cancer incidence between 1998–2001 and 2003–2006 in the SEER 9 registries was greatest among women living in counties with higher median household income (−16% change for ≥$85,000 vs. −4% for <$35,000; P trend < 0.01) and a higher percentage of adults aged 25 years or older with a bachelor’s degree (−13% change for ≥40% vs. −8% for <15%; P trend < 0.01). Counties with higher DCIS incidence during 1985–2001 had a larger decrease in invasive breast cancer incidence (absolute decrease 1.7 percentage points greater per 5 per 100,000 increase in DCIS incidence; P = 0.01). This association was present for both ER-positive and ER-negative invasive cancers (P < 0.05). In summary, the decline in breast cancer incidence has been largest in areas with high socioeconomic status and high screening utilization rates. These results are consistent with the hypothesis that a saturation of screening mammography utilization contributed to the overall decline in breast cancer incidence.
Literatur
1.
Zurück zum Zitat Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMed
3.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059 Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059
4.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMed
5.
Zurück zum Zitat Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332CrossRefPubMed Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332CrossRefPubMed
6.
Zurück zum Zitat Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93(23):1811–1817CrossRefPubMed Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93(23):1811–1817CrossRefPubMed
7.
Zurück zum Zitat Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918CrossRefPubMed Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918CrossRefPubMed
8.
Zurück zum Zitat Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780CrossRefPubMed Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16(12):2773–2780CrossRefPubMed
9.
Zurück zum Zitat Wei F, Miglioretti DL, Connelly MT et al (2005) Changes in women’s use of hormones after the Women’s Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 35:106–112 Wei F, Miglioretti DL, Connelly MT et al (2005) Changes in women’s use of hormones after the Women’s Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 35:106–112
10.
Zurück zum Zitat Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28CrossRefPubMed Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28CrossRefPubMed
11.
Zurück zum Zitat Miller BA, Feuer EJ, Hankey BF (1993) Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 43(1):27–41CrossRefPubMed Miller BA, Feuer EJ, Hankey BF (1993) Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 43(1):27–41CrossRefPubMed
12.
Zurück zum Zitat Newcomb PA, Lantz PM (1993) Recent trends in breast cancer incidence, mortality, and mammography. Breast Cancer Res Treat 28(2):97–106CrossRefPubMed Newcomb PA, Lantz PM (1993) Recent trends in breast cancer incidence, mortality, and mammography. Breast Cancer Res Treat 28(2):97–106CrossRefPubMed
13.
Zurück zum Zitat Breen N, AC K, Meissner HI et al (2007) Reported drop in mammography: is this cause for concern? Cancer 109(12):2405–2409CrossRefPubMed Breen N, AC K, Meissner HI et al (2007) Reported drop in mammography: is this cause for concern? Cancer 109(12):2405–2409CrossRefPubMed
14.
Zurück zum Zitat Morrison AS (1992) Screening in chronic disease, vol 19, 2nd edn. Oxford University Press, New York Morrison AS (1992) Screening in chronic disease, vol 19, 2nd edn. Oxford University Press, New York
15.
Zurück zum Zitat Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91(12):1017–1024CrossRefPubMed Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91(12):1017–1024CrossRefPubMed
16.
Zurück zum Zitat Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database (released April 2009, based on the November 2008 submission). www.seer.cancer.gov Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database (released April 2009, based on the November 2008 submission). www.​seer.​cancer.​gov
17.
Zurück zum Zitat Fritz A, Percy C, Jack A et al (eds) (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva Fritz A, Percy C, Jack A et al (eds) (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
18.
Zurück zum Zitat National Center for Health Statistics (2008) Health, United States, 2008 with chartbook. National Center for Health Statistics, Hyattsville National Center for Health Statistics (2008) Health, United States, 2008 with chartbook. National Center for Health Statistics, Hyattsville
19.
Zurück zum Zitat Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 22:151–156 Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 22:151–156
20.
Zurück zum Zitat Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275(12):913–918CrossRefPubMed Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275(12):913–918CrossRefPubMed
21.
Zurück zum Zitat Devesa SS, Diamond EL (1980) Association of breast cancer and cervical cancer incidence with income and education among whites and blacks. J Natl Cancer Inst 65(3):515–528PubMed Devesa SS, Diamond EL (1980) Association of breast cancer and cervical cancer incidence with income and education among whites and blacks. J Natl Cancer Inst 65(3):515–528PubMed
22.
Zurück zum Zitat Robert SA, Strombom I, Trentham-Dietz A et al (2004) Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology 15(4):442–450CrossRefPubMed Robert SA, Strombom I, Trentham-Dietz A et al (2004) Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology 15(4):442–450CrossRefPubMed
23.
Zurück zum Zitat Katz SJ, Zemencuk JK, Hofer TP (2000) Breast cancer screening in the United States and Canada, 1994: socioeconomic gradients persist. Am J Public Health 90(5):799–803CrossRefPubMed Katz SJ, Zemencuk JK, Hofer TP (2000) Breast cancer screening in the United States and Canada, 1994: socioeconomic gradients persist. Am J Public Health 90(5):799–803CrossRefPubMed
24.
Zurück zum Zitat Heck KE, Pamuk ER (1997) Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol 145(4):366–372PubMed Heck KE, Pamuk ER (1997) Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol 145(4):366–372PubMed
25.
Zurück zum Zitat Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE (2002) The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause 9(4):264–272CrossRefPubMed Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE (2002) The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause 9(4):264–272CrossRefPubMed
26.
Zurück zum Zitat Marks NF, Shinberg DS (1998) Socioeconomic status differences in hormone therapy. Am J Epidemiol 148(6):581–593PubMed Marks NF, Shinberg DS (1998) Socioeconomic status differences in hormone therapy. Am J Epidemiol 148(6):581–593PubMed
27.
Zurück zum Zitat Kerlikowske K, Miglioretti DL, Ballard-Barbash R et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321CrossRefPubMed Kerlikowske K, Miglioretti DL, Ballard-Barbash R et al (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321CrossRefPubMed
28.
Zurück zum Zitat Kerlikowske K, Buist DSM, Walker R (2007) Author reply: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. JNCI 99(23):1816–1817 Kerlikowske K, Buist DSM, Walker R (2007) Author reply: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. JNCI 99(23):1816–1817
29.
Zurück zum Zitat Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9(7):697–703PubMed Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9(7):697–703PubMed
30.
Zurück zum Zitat Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ (2006) A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 36:96–105 Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ (2006) A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 36:96–105
Metadaten
Titel
Socioeconomic disparities in the decline in invasive breast cancer incidence
verfasst von
Brian L. Sprague
Amy Trentham-Dietz
Elizabeth S. Burnside
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0737-y

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.